The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises? W Hall, A Carter, C Forlini The Lancet Psychiatry 2 (1), 105-110, 2015 | 387 | 2015 |
Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders C Forlini, E Racine Neuroethics 2, 163-177, 2009 | 152 | 2009 |
Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Ethics blind spots in current debates E Racine, C Forlini Neuroethics 3, 1-4, 2010 | 151 | 2010 |
Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement C Forlini, E Racine BMC Medical Ethics 10, 1-13, 2009 | 114 | 2009 |
Australian university students’ coping strategies and use of pharmaceutical stimulants as cognitive enhancers C Jensen, C Forlini, B Partridge, W Hall Frontiers in psychology 7, 178540, 2016 | 103 | 2016 |
The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement E Racine, T Martin Rubio, J Chandler, C Forlini, J Lucke Medicine, Health Care and Philosophy 17, 325-337, 2014 | 67 | 2014 |
Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement S Sattler, C Forlini, E Racine, C Sauer PloS one 8 (8), e71452, 2013 | 64 | 2013 |
Stakeholder perspectives and reactions to “academic” cognitive enhancement: Unsuspected meaning of ambivalence and analogies C Forlini, E Racine Public understanding of science 21 (5), 606-625, 2012 | 62 | 2012 |
Ethical issues raised by a ban on the sale of electronic nicotine devices W Hall, C Gartner, C Forlini Addiction 110 (7), 1061-1067, 2015 | 60 | 2015 |
Researchers’ perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey K Riggall, C Forlini, A Carter, W Hall, M Weier, B Partridge, M Meinzer Scientific reports 5 (1), 10618, 2015 | 59 | 2015 |
Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use J Lucke, C Jensen, M Dunn, G Chan, C Forlini, S Kaye, B Partridge, ... BMC Public Health 18, 1-7, 2018 | 58 | 2018 |
Knowledge, experiences and views of German university students toward neuroenhancement: an empirical-ethical analysis C Forlini, J Schildmann, P Roser, R Beranek, J Vollmann Neuroethics 8, 83-92, 2015 | 56 | 2015 |
Expectations regarding cognitive enhancement create substantial challenges E Racine, C Forlini Journal of Medical Ethics 35 (8), 469-470, 2009 | 47 | 2009 |
Food addiction and its impact on weight-based stigma and the treatment of obese individuals in the US and Australia NM Lee, WD Hall, J Lucke, C Forlini, A Carter Nutrients 6 (11), 5312-5326, 2014 | 42 | 2014 |
Navigating the enhancement landscape: Ethical issues in research on cognitive enhancers for healthy individuals C Forlini, W Hall, B Maxwell, SM Outram, PB Reiner, D Repantis, ... EMBO reports 14 (2), 123-128, 2013 | 42 | 2013 |
Brain disease model of addiction: misplaced priorities? W Hall, A Carter, C Forlini The Lancet Psychiatry 2 (10), 867, 2015 | 39 | 2015 |
Should physicians prescribe cognitive enhancers to healthy individuals? C Forlini, S Gauthier, E Racine CMAJ 185 (12), 1047-1050, 2013 | 34 | 2013 |
Performance and image enhancing drug interventions aimed at increasing knowledge among healthcare professionals (HCP): Reflections on the implementation of the Dopinglinkki e … AM Atkinson, K Van De Ven, M Cunningham, T de Zeeuw, E Hibbert, ... International Journal of Drug Policy 95, 103141, 2021 | 33 | 2021 |
Added stakeholders, added value (s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders? C Forlini, E Racine AJOB Primary Research 3 (1), 33-47, 2012 | 33 | 2012 |
Generating genius: how an Alzheimer’s drug became considered a ‘cognitive enhancer’for healthy individuals L Wade, C Forlini, E Racine BMC medical ethics 15, 1-14, 2014 | 28 | 2014 |